Liver transplantation for the treatment of neuroendocrine liver metastases

Valery Vilchez, Roberto Gedaly

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Neuroendocrine neoplasms represent a heterogeneous group of cancers arising from a variety of neuroendocrine cell types. In general, these tumors (NET) are asymptomatic and are discovered late once metastatic disease is present (40-80%). The liver is the most common organ involved when metastases occur (40-93%), followed by bone (12-20%) and lungs (8-10%). A number of different therapeutic options are available for patients with hepatic metastases including surgical resection, transplantation, transarterial chemoembolization, radiofrequency and microwave ablation, radioembolization (Y90), chemotherapy, somatostatin analogues and molecular targeted therapies. Surgical resection is still considered the treatment of choice and provides excellent disease control with an overall survival of 47-92%. Liver transplantation has been advocated in selected patients with bilateral unresectable symptomatic liver metastases. The aim of this study is to review the existing literature emphasizing on the role of transplantation to treat patients with liver metastases from NET.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number1
StatePublished - Jan 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Ltd.


  • UNOS database
  • liver metastases
  • liver transplantation
  • neuroendocrine tumors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Liver transplantation for the treatment of neuroendocrine liver metastases'. Together they form a unique fingerprint.

Cite this